Pharmaceutical Business Investment Opportunities in Himachal Pradesh

- Manufacturing govt. approved Ayurvedic medicines under our own branded products. - WHO approved manufacturing facility nestled in the Himalayan foothills. - We have a valid incorporation and GMP certificate. - Previously engaged in OEMs, but not presently. - Ample manufacturing capacity to meet demand. - 7 years of industry experience. - Distribution channels include hospital tie-ups in Punjab, Amazon, and our website, with primary revenue stemming from hospital tie-ups. - Registered in Delhi, but operations are based in Himachal Pradesh. - Currently operating at breakeven, encountering challenges post the demise of a key founder. - Current employee count is necessary to mange operations at scale. - The manufacturing capacity per annum is as follows: Tablet - 4 million tablets. Liquid syrups / suspension / juices- 5 million bottles. Capsules- 2.5 million capsules. Ointment / Cream / Lotion- 3 million tubes. Powder- 5 MT powder. Paste -1 MT paste. Eye drop- 0.5 million bottles.

1. The business operates in the generic pharmaceuticals industry, offering a wide range of tablets except narcotics-related products. 2. Located in Baddi, the company adheres to Good Manufacturing Practice (GMP) and World Health Organization (WHO) Drugs and Cosmetics guidelines for its machinery and facilities. 3. The business boasts Microbiological and Chemical laboratories compliant with the latest guidelines, ensuring quality control and regulatory compliance. 5. The owner, who has prior experience in manufacturing and runs a successful marketing company, possesses valuable connections within the pharmaceutical industry. 6. With plans to operate at 50% capacity in the next 6 months, the business projects sales of over INR 50 crores, with an expected net profit of INR 8 crores, reflecting a strong revenue and profitability outlook. 7. The business benefits from the owner's industry expertise and established relationships with pharmaceutical clients, which may contribute to its growth and success. 8. The focus on generic pharmaceuticals and compliance with industry standards positions the business to capitalize on the growing demand for affordable and accessible medication. 9. The company was incorporated in 2019 but was not able to start operations due to the covid crisis, the promoters are looking to start the business now and are also work on the lab to ensure that the required licenses are in place.